KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Operating Leases (2022 - 2025)

Ginkgo Bioworks Holdings' Operating Leases history spans 4 years, with the latest figure at $417.1 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 4.94% year-over-year to $417.1 million; the TTM value through Dec 2025 reached $417.1 million, down 4.94%, while the annual FY2025 figure was $417.1 million, 4.94% down from the prior year.
  • Operating Leases reached $417.1 million in Q4 2025 per DNA's latest filing, down from $422.9 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $452.3 million in Q2 2024 to a low of $221.8 million in Q4 2023.
  • Average Operating Leases over 4 years is $394.5 million, with a median of $417.1 million recorded in 2025.
  • Peak YoY movement for Operating Leases: tumbled 46.32% in 2023, then surged 97.79% in 2024.
  • A 4-year view of Operating Leases shows it stood at $413.3 million in 2022, then tumbled by 46.32% to $221.8 million in 2023, then surged by 97.79% to $438.8 million in 2024, then dropped by 4.94% to $417.1 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Operating Leases are $417.1 million (Q4 2025), $422.9 million (Q3 2025), and $428.8 million (Q2 2025).